[go: up one dir, main page]

AR086511A2 - UNION AGENTS SPECIFIC TO THE GROWTH FACTOR OF HEPATOCITS - Google Patents

UNION AGENTS SPECIFIC TO THE GROWTH FACTOR OF HEPATOCITS

Info

Publication number
AR086511A2
AR086511A2 ARP120101799A ARP120101799A AR086511A2 AR 086511 A2 AR086511 A2 AR 086511A2 AR P120101799 A ARP120101799 A AR P120101799A AR P120101799 A ARP120101799 A AR P120101799A AR 086511 A2 AR086511 A2 AR 086511A2
Authority
AR
Argentina
Prior art keywords
residue
seq
amino acid
acid sequence
antibody
Prior art date
Application number
ARP120101799A
Other languages
Spanish (es)
Original Assignee
Amgen Inc
Abgenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Abgenix Inc filed Critical Amgen Inc
Publication of AR086511A2 publication Critical patent/AR086511A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Cosmetics (AREA)

Abstract

Reivindicación 1: Un anticuerpo aislado que es capaz de neutralizar la unión de HGF a c-Met y que compite por la unión a HGF con al menos un anticuerpo seleccionado de: un anticuerpo que comprende una cadena liviana que comprende la secuencia de aminoácidos de SEQ ID Nº 24 desde el residuo 23 hasta el residuo 129 y una cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 25 desde el residuo 20 hasta el residuo 141; un anticuerpo que comprende una cadena liviana que comprende la secuencia de aminoácidos de SEQ ID Nº 26 desde el residuo 21 hasta el residuo 133 y una cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 27 desde el residuo 20 hasta el residuo 137; un anticuerpo que comprende una cadena liviana que comprende la secuencia de aminoácidos de SEQ ID Nº 28 desde el residuo 23 hasta el residuo 129 y una cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 29 desde el residuo 20 hasta el residuo 139; un anticuerpo que comprende una cadena liviana que comprende la secuencia de aminoácidos de SEQ ID Nº 30 desde el residuo 23 hasta el residuo 129 y una cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 31 desde el residuo 20 hasta el residuo 148; un anticuerpo que comprende una cadena liviana que comprende la secuencia de aminoácidos de SEQ ID Nº 32 desde el residuo 23 hasta el residuo 129 y una cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 33 desde el residuo 20 hasta el residuo 139; un anticuerpo que comprende una cadena liviana que comprende la secuencia de aminoácidos de SEQ ID Nº 34 desde el residuo 23 hasta el residuo 129 y una cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 35 desde el residuo 20 hasta el residuo 144; un anticuerpo que comprende una cadena liviana que comprende la secuencia de aminoácidos de SEQ ID Nº 36 desde el residuo 21 hasta el residuo 133 y una cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 37 desde el residuo 20 hasta el residuo 142; un anticuerpo que comprende una cadena liviana que comprende la secuencia de aminoácidos de SEQ ID Nº 38 desde el residuo 21 hasta el residuo 128 y una cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 39 desde el residuo 20 hasta el residuo 139; un anticuerpo que comprende una cadena liviana que comprende la secuencia de aminoácidos de SEQ ID Nº 40 desde el residuo 23 hasta el residuo 129 y una cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 41 desde el residuo 20 hasta el residuo 140; y un anticuerpo que comprende una cadena liviana que comprende la secuencia de aminoácidos de SEQ ID Nº 42 desde el residuo 21 hasta el residuo 128 y una cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 43 desde el residuo 20 hasta el residuo 139.Reivindicación 5: Una célula huésped caracterizada porque comprende un primer polinucleótido que codifica una cadena liviana y un segundo polinucleótido que codifica una cadena pesada, donde la cadena liviana y la cadena pesada son capaces de formar un anticuerpo que puede neutralizar la unión de HGF a c-Met y que compite por la unión a HGF con al menos un anticuerpo seleccionado de: un anticuerpo que comprende una cadena liviana que comprende la secuencia de aminoácidos de SEQ ID Nº 24 desde el residuo 23 hasta el residuo 129 y una cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 25 desde el residuo 20 hasta el residuo 141; un anticuerpo que comprende una cadena liviana que comprende la secuencia de aminoácidos de SEQ ID Nº 26 desde el residuo 21 hasta el residuo 133 y una cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 27 desde el residuo 20 hasta el residuo 137; un anticuerpo que comprende una cadena liviana que comprende la secuencia de aminoácidos de SEQ ID Nº 28 desde el residuo 23 hasta el residuo 129 y una cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 29 desde el residuo 20 hasta el residuo 139; un anticuerpo que comprende una cadena liviana que comprende la secuencia de aminoácidos de SEQ ID Nº 30 desde el residuo 23 hasta el residuo 129 y una cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 31 desde el residuo 20 hasta el residuo 148; un anticuerpo que comprende una cadena liviana que comprende la secuencia de aminoácidos de SEQ ID Nº 32 desde el residuo 23 hasta el residuo 129 y una cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 33 desde el residuo 20 hasta el residuo 139; un anticuerpo que comprende una cadena liviana que comprende la secuencia de aminoácidos de SEQ ID Nº 34 desde el residuo 23 hasta el residuo 129 y una cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 35 desde el residuo 20 hasta el residuo 144; un anticuerpo que comprende una cadena liviana que comprende la secuencia de aminoácidos de SEQ ID Nº 36 desde el residuo 21 hasta el residuo 133 y una cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 37 desde el residuo 20 hasta el residuo 142; un anticuerpo que comprende una cadena liviana que comprende la secuencia de aminoácidos de SEQ ID Nº 38 desde el residuo 21 hasta el residuo 128 y una cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 39 desde el residuo 20 hasta el residuo 139; un anticuerpo que comprende una cadena liviana que comprende la secuencia de aminoácidos de SEQ ID Nº 40 desde el residuo 23 hasta el residuo 129 y una cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 41 desde el residuo 20 hasta el residuo 140; y un anticuerpo que comprende una cadena liviana que comprende la secuencia de aminoácidos de SEQ ID Nº 42 desde el residuo 21 hasta el residuo 128 y una cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 43 desde el residuo 20 hasta el residuo 139. Reivindicación 8: Uso del anticuerpo de acuerdo con cualquiera de las reivindicaciones 1 a 3, caracterizado porque es para la preparación de un medicamento para el tratamiento del cáncer.Claim 1: An isolated antibody that is capable of neutralizing the binding of HGF to c-Met and that competes for binding to HGF with at least one antibody selected from: an antibody comprising a light chain comprising the amino acid sequence of SEQ ID No. 24 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID No. 25 from residue 20 to residue 141; an antibody comprising a light chain comprising the amino acid sequence of SEQ ID No. 26 from residue 21 to residue 133 and a heavy chain comprising the amino acid sequence of SEQ ID No. 27 from residue 20 to residue 137; an antibody comprising a light chain comprising the amino acid sequence of SEQ ID No. 28 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID No. 29 from residue 20 to residue 139; an antibody comprising a light chain comprising the amino acid sequence of SEQ ID No. 30 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID No. 31 from residue 20 to residue 148; an antibody comprising a light chain comprising the amino acid sequence of SEQ ID No. 32 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID No. 33 from residue 20 to residue 139; an antibody comprising a light chain comprising the amino acid sequence of SEQ ID No. 34 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID No. 35 from residue 20 to residue 144; an antibody comprising a light chain comprising the amino acid sequence of SEQ ID No. 36 from residue 21 to residue 133 and a heavy chain comprising the amino acid sequence of SEQ ID No. 37 from residue 20 to residue 142; an antibody comprising a light chain comprising the amino acid sequence of SEQ ID No. 38 from residue 21 to residue 128 and a heavy chain comprising the amino acid sequence of SEQ ID No. 39 from residue 20 to residue 139; an antibody comprising a light chain comprising the amino acid sequence of SEQ ID No. 40 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID No. 41 from residue 20 to residue 140; and an antibody comprising a light chain comprising the amino acid sequence of SEQ ID No. 42 from residue 21 to residue 128 and a heavy chain comprising the amino acid sequence of SEQ ID No. 43 from residue 20 to residue 139 Claim 5: A host cell characterized in that it comprises a first polynucleotide that encodes a light chain and a second polynucleotide that encodes a heavy chain, where the light chain and the heavy chain are capable of forming an antibody that can neutralize HGF binding to c-Met and competing for binding to HGF with at least one antibody selected from: an antibody comprising a light chain comprising the amino acid sequence of SEQ ID No. 24 from residue 23 to residue 129 and a heavy chain that comprises the amino acid sequence of SEQ ID No. 25 from residue 20 to residue 141; an antibody comprising a light chain comprising the amino acid sequence of SEQ ID No. 26 from residue 21 to residue 133 and a heavy chain comprising the amino acid sequence of SEQ ID No. 27 from residue 20 to residue 137; an antibody comprising a light chain comprising the amino acid sequence of SEQ ID No. 28 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID No. 29 from residue 20 to residue 139; an antibody comprising a light chain comprising the amino acid sequence of SEQ ID No. 30 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID No. 31 from residue 20 to residue 148; an antibody comprising a light chain comprising the amino acid sequence of SEQ ID No. 32 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID No. 33 from residue 20 to residue 139; an antibody comprising a light chain comprising the amino acid sequence of SEQ ID No. 34 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID No. 35 from residue 20 to residue 144; an antibody comprising a light chain comprising the amino acid sequence of SEQ ID No. 36 from residue 21 to residue 133 and a heavy chain comprising the amino acid sequence of SEQ ID No. 37 from residue 20 to residue 142; an antibody comprising a light chain comprising the amino acid sequence of SEQ ID No. 38 from residue 21 to residue 128 and a heavy chain comprising the amino acid sequence of SEQ ID No. 39 from residue 20 to residue 139; an antibody comprising a light chain comprising the amino acid sequence of SEQ ID No. 40 from residue 23 to residue 129 and a heavy chain comprising the amino acid sequence of SEQ ID No. 41 from residue 20 to residue 140; and an antibody comprising a light chain comprising the amino acid sequence of SEQ ID No. 42 from residue 21 to residue 128 and a heavy chain comprising the amino acid sequence of SEQ ID No. 43 from residue 20 to residue 139 Claim 8: Use of the antibody according to any of claims 1 to 3, characterized in that it is for the preparation of a medicament for the treatment of cancer.

ARP120101799A 2003-07-18 2012-05-21 UNION AGENTS SPECIFIC TO THE GROWTH FACTOR OF HEPATOCITS AR086511A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48868103P 2003-07-18 2003-07-18

Publications (1)

Publication Number Publication Date
AR086511A2 true AR086511A2 (en) 2013-12-18

Family

ID=34193077

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP040102530A AR042955A1 (en) 2003-07-18 2004-07-16 UNION AGENTS SPECIFIC TO THE GROWTH FACTOR OF HEPATOCITS
ARP120101799A AR086511A2 (en) 2003-07-18 2012-05-21 UNION AGENTS SPECIFIC TO THE GROWTH FACTOR OF HEPATOCITS
ARP120101798A AR086510A2 (en) 2003-07-18 2012-05-21 UNION AGENTS SPECIFIC TO THE GROWTH FACTOR OF HEPATOCITS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP040102530A AR042955A1 (en) 2003-07-18 2004-07-16 UNION AGENTS SPECIFIC TO THE GROWTH FACTOR OF HEPATOCITS

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP120101798A AR086510A2 (en) 2003-07-18 2012-05-21 UNION AGENTS SPECIFIC TO THE GROWTH FACTOR OF HEPATOCITS

Country Status (26)

Country Link
US (2) US8609090B2 (en)
EP (2) EP1648998B1 (en)
JP (4) JP5105874B2 (en)
KR (2) KR20110129988A (en)
CN (3) CN103755807A (en)
AR (3) AR042955A1 (en)
AU (1) AU2004265595B2 (en)
BR (1) BRPI0412885A (en)
CA (1) CA2532027C (en)
DK (1) DK1648998T3 (en)
EA (1) EA015363B1 (en)
ES (1) ES2523837T3 (en)
HK (1) HK1199266A1 (en)
IL (1) IL172906A0 (en)
ME (1) MEP31408A (en)
MX (1) MXPA06000508A (en)
NO (1) NO20060600L (en)
NZ (1) NZ544797A (en)
PL (1) PL1648998T3 (en)
PT (1) PT1648998E (en)
RS (1) RS53476B (en)
SG (1) SG131943A1 (en)
SI (1) SI1648998T1 (en)
TW (3) TW201319088A (en)
WO (1) WO2005017107A2 (en)
ZA (2) ZA200601353B (en)

Families Citing this family (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
CN103755807A (en) * 2003-07-18 2014-04-30 安姆根有限公司 Specific binding agents to hepatocyte growth factor
HN2004000285A (en) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTIBODIES DIRECTED TO c-MET
US7046714B2 (en) * 2003-09-10 2006-05-16 Intel Corporation Method and apparatus for Raman ring resonator based laser/wavelength converter
EP2927322A1 (en) * 2004-06-10 2015-10-07 Viventia Bio Inc. Tumor specific antibody
US20090304635A1 (en) 2005-03-29 2009-12-10 George Cotsarelis Methods for generating new hair follicles, treating baldness, and hair removal
CN101193910A (en) 2005-04-15 2008-06-04 健泰科生物技术公司 HGF beta chain variant
BRPI0611009A2 (en) * 2005-06-02 2010-08-10 Galaxy Biotech Llc uses of a monoclonal antibody (mab), and a neutralizing anti-hgf antibody
JP2009504685A (en) * 2005-08-15 2009-02-05 アラーナ・テラピューティクス・リミテッド Engineered antibodies using the New World primate framework region
CA2634083A1 (en) * 2005-12-20 2007-06-28 Arana Therapeutics Limited Chimeric antibodies with part new world primate binding regions
AU2007211829C9 (en) * 2006-02-01 2013-07-11 Cephalon Australia Pty Ltd Domain antibody construct
AR059922A1 (en) 2006-04-01 2008-05-07 Galaxy Biotech Llc HUMANIZED MONOCLONAL ANTIBODIES FOR THE GROWTH FACTOR OF HEPATOCITS
JP4686634B2 (en) * 2006-06-02 2011-05-25 アベオ ファーマシューティカルズ， インコーポレイテッド Hepatocyte growth factor (HGF) binding protein
EP2029627B1 (en) 2006-06-02 2011-11-16 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (hgf) binding proteins
CL2007002225A1 (en) * 2006-08-03 2008-04-18 Astrazeneca Ab SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A
CL2007002567A1 (en) 2006-09-08 2008-02-01 Amgen Inc ISOLATED PROTEINS FROM LINK TO ACTIVINE TO HUMAN.
JP2010504974A (en) 2006-09-28 2010-02-18 フォリカ，インコーポレーテッド Methods, kits, and compositions for generating new hair follicles and growing hair
US20080139790A1 (en) * 2006-12-08 2008-06-12 Jennings Philip A Chimeric antibodies
CA2692165A1 (en) * 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
JP5570989B2 (en) * 2007-08-31 2014-08-13 アムジエン・インコーポレーテツド Solid protein formulation
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
JP5963341B2 (en) 2007-09-14 2016-08-10 アムジエン・インコーポレーテツド Homogeneous antibody population
CA2701032C (en) 2007-09-27 2021-01-26 Amgen Inc. Pharmaceutical formulations
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
PE20091827A1 (en) * 2008-04-11 2009-11-20 Galaxy Biotech Llc COMBINATION OF INHIBITOR HGF AND INHIBITOR EGF FOR THE TREATMENT OF CANCER
PE20091714A1 (en) * 2008-04-11 2009-11-15 Galaxy Biotech Llc COMBINATION OF THE INHIBITOR HGF AND THE AGONIST PTEN
JP5646457B2 (en) * 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド Dual variable domain immunoglobulins and uses thereof
AU2009255305B2 (en) 2008-05-29 2014-10-30 Galaxy Biotech, Llc Monoclonal antibodies to basic fibroblast growth factor
JP2011523853A (en) 2008-06-03 2011-08-25 アボット・ラボラトリーズ Dual variable domain immunoglobulins and uses thereof
RU2010153578A (en) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAINS AND THEIR APPLICATION
US8822645B2 (en) * 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
AU2013202400B2 (en) * 2008-07-16 2014-10-09 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
UA112050C2 (en) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі THERAPEUTIC COMPOSITION CONTAINING MONOCLONAL ANTIBODY AGAINST TISSUE FACTOR INHIBITOR (TFPI)
MX2011003363A (en) * 2008-10-01 2011-04-27 Ludwig Inst Cancer Res Methods for the treatment of cancer.
DK2842573T3 (en) 2008-11-07 2017-10-30 Galaxy Biotech Llc Monoclonal antibodies to fibroblast growth factor receptor 2
SG2014006878A (en) * 2008-11-12 2014-04-28 Merck Sharp & Dohme ßGI-IGG INTRON FOR ENHANCED ANTI-IGF1 R EXPRESSION
US20120052064A1 (en) 2009-04-17 2012-03-01 Yuuki Ito Anti-hgf antibody combinational cancer therapies
RU2011148918A (en) * 2009-05-01 2013-06-10 Эбботт Лэборетриз IMMUNOGLOBULIN WITH TWO VARIABLE DOMAINS AND ITS APPLICATION
UY32808A (en) * 2009-07-29 2011-02-28 Abbott Lab IMMUNOGLOBULINS AS A DUAL VARIABLE DOMAIN AND USES OF THE SAME
IN2012DN02737A (en) 2009-09-01 2015-09-11 Abbott Lab
CA2774199C (en) * 2009-09-16 2018-11-13 Mipsalus Aps Improved purification of multi-specific receptors
PE20121531A1 (en) * 2009-10-15 2012-12-22 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN
EP2490957B1 (en) 2009-10-23 2016-11-23 Amgen, Inc Vial adapter and system
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
SI2542257T1 (en) 2010-03-01 2018-01-31 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
RS54291B2 (en) 2010-06-07 2023-12-29 Amgen Inc Drug delivery device
AU2011267869A1 (en) 2010-06-14 2013-01-10 Vaccinex, Inc. Anti-VEGF antibodies and uses thereof
EP2588107A1 (en) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
BR112013002578A2 (en) 2010-08-03 2019-05-14 Abbvie Inc. double variable domain immunoglobins and their uses
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
MX2013002270A (en) 2010-08-26 2013-05-14 Abbvie Inc Dual variable domain immunoglobulins and uses thereof.
WO2012044577A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
EP3590949B1 (en) 2010-10-01 2022-05-18 ModernaTX, Inc. Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof
AU2011333738A1 (en) 2010-11-24 2013-07-11 Glaxo Group Limited Multispecific antigen binding proteins targeting HGF
WO2012078649A1 (en) 2010-12-06 2012-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
ES2489475T3 (en) * 2011-03-18 2014-09-02 Metheresis Translational Research Sa MET inhibitors to enhance the effectiveness of radiotherapy
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9480624B2 (en) 2011-03-31 2016-11-01 Amgen Inc. Vial adapter and system
CA3021845C (en) 2011-04-20 2022-03-29 Amgen Inc. Autoinjector apparatus
EP4306165A3 (en) * 2011-07-01 2024-04-17 NGM Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
KR20140067052A (en) 2011-09-09 2014-06-03 암젠 인코퍼레이티드 Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS62993B1 (en) 2011-10-03 2022-03-31 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
IL308846B2 (en) 2011-10-14 2025-03-01 Amgen Inc Injector and method of assembly
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
CN104159920A (en) 2011-12-30 2014-11-19 艾伯维公司 Dual specific binding proteins directed against il-13 and/or il-17
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
JP2015513912A (en) 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US9441039B2 (en) 2012-05-07 2016-09-13 Amgen Inc. Anti-erythropoietin antibodies
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
WO2014058389A1 (en) 2012-10-12 2014-04-17 Agency For Science, Technology And Research Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics
TW202210507A (en) 2012-11-01 2022-03-16 美商艾伯維有限公司 Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
EP3081249B1 (en) 2012-11-21 2020-12-30 Amgen Inc. Drug delivery device
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
SG11201503938VA (en) * 2012-11-21 2015-06-29 Janssen Biotech Inc BISPECIFIC EGFR/c-Met ANTIBODIES
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
PL2922554T3 (en) 2012-11-26 2022-06-20 Modernatx, Inc. Terminally modified rna
ES2828505T3 (en) 2012-11-28 2021-05-26 Ngm Biopharmaceuticals Inc Compositions and methods for the treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9925242B2 (en) 2012-12-27 2018-03-27 Ngm Biopharmaceuticals, Inc. Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of nonalcoholic steatohepatitis
WO2014108854A1 (en) 2013-01-09 2014-07-17 Fusimab Ltd. Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
EP2968460B1 (en) 2013-03-11 2021-01-06 Amgen Inc. Protein formulations
US9481725B2 (en) 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
EP2964673A4 (en) * 2013-03-14 2017-02-22 Alder Biopharmaceuticals, Inc. Antibodies to hgf and compositions containing
EP2970459A2 (en) 2013-03-15 2016-01-20 AbbVie Inc. Dual specific binding proteins directed against il-1beta and il-17
TWI580451B (en) 2013-03-15 2017-05-01 安美基公司 Cassette for an injector and method of using an autoinjector apparatus having an autoinjector and a cassette
TWI639449B (en) 2013-03-15 2018-11-01 美商安美基公司 Cassette for an injector
TWI592183B (en) 2013-03-15 2017-07-21 安美基公司 Automatic injector device with adjustable body contour
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
KR102287687B1 (en) 2013-03-22 2021-08-06 암젠 인크 Injector and method of assembly
KR102060540B1 (en) 2013-04-03 2019-12-31 삼성전자주식회사 Pharmaceutical composition for a combination therapy containing an anti-c-Met antibody and anti-Ang2 antibody
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
CN105980401A (en) 2013-10-03 2016-09-28 现代治疗公司 Polynucleotides encoding low density lipoprotein receptor
EP3789064B1 (en) 2013-10-24 2024-11-27 Amgen Inc. Injector and method of assembly
US10758683B2 (en) 2013-10-24 2020-09-01 Amgen Inc. Drug delivery system with temperature-sensitive control
US10994112B2 (en) 2014-02-05 2021-05-04 Amgen Inc. Drug delivery system with electromagnetic field generator
MX2016012285A (en) 2014-03-24 2017-01-23 Genentech Inc Cancer treatment with c-met antagonists and correlation of the latter with hgf expression.
CA2945026C (en) 2014-05-07 2023-10-10 Amgen Inc. Autoinjector with shock reducing elements
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
EP4362039A3 (en) 2014-06-03 2024-08-07 Amgen Inc. Controllable drug delivery system and method of use
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
MX2021014323A (en) 2014-10-14 2023-02-02 Amgen Inc Drug injection device with visual and audio indicators.
RU2729161C2 (en) 2014-10-23 2020-08-04 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Pharmaceutical compositions containing peptide versions, and methods of using them
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
ES2785311T3 (en) 2014-12-19 2020-10-06 Amgen Inc Mobile button drug delivery device or user interface field
ES2898469T3 (en) 2014-12-19 2022-03-07 Amgen Inc Medication administration device with proximity sensor
CA2976935C (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
EP3981450A1 (en) 2015-02-27 2022-04-13 Amgen, Inc Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
ES2739749T3 (en) * 2015-05-18 2020-02-03 Tolero Pharmaceuticals Inc Alvocidib prodrugs that have increased bioavailability
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
CN108289861B (en) 2015-08-03 2021-11-02 大日本住友制药肿瘤公司 Combination therapy for the treatment of cancer
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
EP3356415B1 (en) 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
CN106589128B (en) * 2015-10-20 2020-03-03 天津医科大学 Preparation and application of liver cancer marker monoclonal antibody
CN109195626B (en) 2015-10-30 2022-09-13 银河生物技术有限责任公司 Antibodies that bind to death receptor 4 and death receptor 5
EP3888672A1 (en) 2015-11-09 2021-10-06 NGM Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
CN106674350B (en) * 2015-11-09 2020-03-03 天津医科大学 Preparation and application of liver cancer marker single-chain antibody
ES2755717T3 (en) 2015-12-09 2020-04-23 Amgen Inc Autoinjector with signaling cap
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
EP4035711B1 (en) 2016-03-15 2025-06-04 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
ES2959783T3 (en) 2016-05-13 2024-02-28 Amgen Inc Vial Protective Cover Assembly
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
AU2017273857B2 (en) 2016-06-01 2021-08-19 Athira Pharma, Inc. Compounds
EP3465124A1 (en) 2016-06-03 2019-04-10 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
US11285266B2 (en) 2016-07-01 2022-03-29 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
US11370841B2 (en) 2016-08-26 2022-06-28 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
EP3532127A1 (en) 2016-10-25 2019-09-04 Amgen Inc. On-body injector
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
US20190358411A1 (en) 2017-01-17 2019-11-28 Amgen Inc. Injection devices and related methods of use and assembly
JP7064501B2 (en) 2017-02-17 2022-05-10 アムジエン・インコーポレーテツド Drug delivery device with sterile fluid flow path and related assembly methods
CA3052204A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Insertion mechanism for drug delivery device
CA3050927A1 (en) 2017-03-06 2018-09-13 Brian Stonecipher Drug delivery device with activation prevention feature
IL268478B2 (en) 2017-03-07 2023-10-01 Amgen Inc Needle insertion by overpressure
CA3052310A1 (en) 2017-03-09 2018-09-13 Amgen Inc. Insertion mechanism for drug delivery device
HUE063805T2 (en) 2017-03-28 2024-01-28 Amgen Inc Plunger rod and syringe assembly system and method
IL269534B2 (en) 2017-03-30 2025-01-01 Univ Queensland Chimeric molecules and uses thereof
MX2019014615A (en) 2017-06-08 2020-02-07 Amgen Inc Torque driven drug delivery device.
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
EP3641857A1 (en) 2017-06-22 2020-04-29 Amgen Inc. Device activation impact/shock reduction
AU2018290302B2 (en) 2017-06-23 2024-02-29 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
ES2972207T3 (en) 2017-07-14 2024-06-11 Amgen Inc Needle insertion-retraction system with double torsion spring system
JP7649105B2 (en) 2017-07-21 2025-03-19 アムジエン・インコーポレーテツド Gas-permeable sealing member for drug containers and method of assembly - Patents.com
MA49676A (en) 2017-07-25 2020-06-03 Amgen Inc DRUG ADMINISTRATION DEVICE EQUIPPED WITH A CONTAINER ACCESS SYSTEM AND ASSOCIATED ASSEMBLY PROCEDURE
US11617837B2 (en) 2017-07-25 2023-04-04 Amgen Inc. Drug delivery device with gear module and related method of assembly
MA49838A (en) 2017-08-09 2020-06-17 Amgen Inc DRUG DELIVERY SYSTEM WITH CHAMBER HYDRAULIC-PNEUMATIC PRESSURE
WO2019036181A1 (en) 2017-08-18 2019-02-21 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. Treatment regimen for cancers that are insensitive to bcl-2 inhibitors using the mcl-1 inhibitor alvocidib
US11759565B2 (en) 2017-10-04 2023-09-19 Amgen Inc. Flow adapter for drug delivery device
EP3691716B1 (en) 2017-10-06 2023-11-29 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
EP3694578B1 (en) 2017-10-09 2025-09-24 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
MA50528A (en) 2017-11-03 2020-09-09 Amgen Inc SYSTEMS AND APPROACHES TO STERILIZE A DRUG DELIVERY DEVICE
MA50553A (en) 2017-11-06 2020-09-16 Amgen Inc DRUG ADMINISTRATION DEVICE WITH POSITIONING AND FLOW DETECTION
EP3707075A1 (en) 2017-11-06 2020-09-16 Amgen Inc. Fill-finish assemblies and related methods
MX2020004736A (en) 2017-11-10 2020-08-13 Amgen Inc Plungers for drug delivery devices.
WO2019099324A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Door latch mechanism for drug delivery device
SG11202002772VA (en) 2017-11-16 2020-04-29 Amgen Inc Autoinjector with stall and end point detection
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
MA53375A (en) 2018-07-24 2021-06-02 Amgen Inc ADMINISTRATION DEVICES FOR THE ADMINISTRATION OF MEDICINES
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
CN112469454B (en) 2018-07-24 2024-01-26 安进公司 Delivery devices for administering drugs
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
US12109389B2 (en) 2018-07-31 2024-10-08 Amgen Inc. Fluid path assembly for a drug delivery device
CA3106452A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
EP3856283A1 (en) 2018-09-28 2021-08-04 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
WO2020072577A1 (en) 2018-10-02 2020-04-09 Amgen Inc. Injection systems for drug delivery with internal force transmission
EP3860686A1 (en) 2018-10-05 2021-08-11 Amgen Inc. Drug delivery device having dose indicator
AR116703A1 (en) 2018-10-15 2021-06-02 Amgen Inc PLATFORM ASSEMBLY PROCESS FOR A DRUG MANAGEMENT DEVICE
EA202191037A1 (en) 2018-10-15 2021-08-05 Эмджен Инк. A DRUG DELIVERY DEVICE WITH A DAMPER MECHANISM
MA54048A (en) 2018-11-01 2022-02-09 Amgen Inc DRUG DELIVERY DEVICES WITH PARTIAL RETRACTION OF DRUG DELIVERY BODY
IL281908B2 (en) 2018-11-01 2025-06-01 Amgen Inc Drug delivery devices with partial drug delivery unit withdrawal
TWI831847B (en) 2018-11-01 2024-02-11 美商安進公司 Drug delivery devices with partial needle retraction and methods for operating the same
WO2020117988A1 (en) 2018-12-04 2020-06-11 Tolero Pharmaceuticals, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
MX2021012557A (en) 2019-04-24 2021-11-12 Amgen Inc SETS AND METHODS OF VERIFICATION OF STERILIZATION OF SYRINGES.
CN114206942A (en) 2019-06-07 2022-03-18 美国安进公司 Bispecific binding constructs
EP3772518A1 (en) * 2019-08-07 2021-02-10 Merus N.V. Modified human variable domains
WO2021028081A1 (en) 2019-08-12 2021-02-18 Interna Technologies B.V. New treatments involving mirna-193a
CA3148261A1 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
AU2021227002A1 (en) 2020-02-28 2022-09-15 Interna Technologies B.V. miRNA-193a for promoting immunogenic cell death
WO2021247812A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Bispecific binding constructs
KR20230117397A (en) 2020-12-03 2023-08-08 암젠 인크 Molecules with Multiple Binding Domains
US20240327503A1 (en) * 2021-03-12 2024-10-03 Jimmy Dale GOLLIHAR Sars-cov-2 neutralizing antibodies and uses thereof
EP4341161A1 (en) 2021-05-21 2024-03-27 Amgen Inc. Method of optimizing a filling recipe for a drug container
UY40783A (en) 2023-06-12 2024-12-31 Amgen Inc LYMPHOTOXIN BETA RECEPTOR AGONIST BINDING PROTEINS

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE87659T1 (en) 1986-09-02 1993-04-15 Enzon Lab Inc BINDING MOLECULES WITH SINGLE POLYPEPTIDE CHAIN.
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
JPS6427491A (en) 1987-07-14 1989-01-30 Yasushi Daikuhara Monoclonal antibody
US5520914A (en) * 1987-08-06 1996-05-28 President And Fellows Of Harvard College Antibodies to angiogenin: immunotherapeutic agents
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
JP3030312B2 (en) * 1988-12-12 2000-04-10 敏一 中村 Mature hepatocyte growth factor (I)
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5086164A (en) * 1989-01-10 1992-02-04 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
JP2762522B2 (en) 1989-03-06 1998-06-04 藤沢薬品工業株式会社 Angiogenesis inhibitor
JPH02240100A (en) * 1989-03-15 1990-09-25 Takara Shuzo Co Ltd Novel polypeptide
AU648505B2 (en) 1989-05-19 1994-04-28 Amgen, Inc. Metalloproteinase inhibitor
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5871959A (en) * 1989-12-27 1999-02-16 The United States Of America As Represented By The Department Of Health And Human Services Method of producing hepatocycte growth factor/scatter factor and related cell lines
US5362716A (en) * 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
GB9003621D0 (en) 1990-02-16 1990-04-11 Imp Cancer Res Tech Protein factor
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
DE69133492T2 (en) 1990-06-11 2006-08-10 Nakamura, Toshikazu Recombinant human hepatocyte growth factor and method for its production
DE69133476T2 (en) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgenic mice capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5821223A (en) * 1990-09-14 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating cell growth with a novel broad spectrum human lung fibroblast-derived mitogen
EP0478101B1 (en) 1990-09-24 2001-08-29 W.R. Grace & Co.-Conn. Therapeutic use of peptides having thrombospondin-like activity
US5892112A (en) 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
US5268384A (en) * 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
WO1992010210A1 (en) 1990-12-14 1992-06-25 E.I. Du Pont De Nemours And Company Inhibition of angiogenesis by il-1
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE122004000008I1 (en) * 1991-06-14 2005-06-09 Genentech Inc Humanized heregulin antibody.
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
ES2341666T3 (en) 1991-12-02 2010-06-24 Medimmune Limited PRODUCTION OF AUTHORTIC BODIES OF REPERTORIES OF ANTIQUE RPOS SEGMENTS EXPRESSED ON THE FAGOS SURFACE.
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
JP4157160B2 (en) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド Methods for the preparation of modified antibody variable regions
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5763584A (en) * 1992-05-18 1998-06-09 Genentech, Inc. Receptor activation with hepatocyte growth factor agonists
AU675968B2 (en) 1992-09-18 1997-02-27 United States Of America, As Represented By The Secretary, Department Of Health And Human Services A method of preventing tumor metastasis
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
ES2279508T3 (en) 1992-11-13 2007-08-16 Immunex Corporation LIGANDO ELK, A CYTOQUINE.
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
WO1994021678A1 (en) * 1993-03-23 1994-09-29 Taisho Pharmaceutical Co., Ltd. Hepatic parenchymal cell growth substance
US5516658A (en) 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
WO1995028484A1 (en) 1994-04-15 1995-10-26 Amgen Inc. Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5919905A (en) 1994-10-05 1999-07-06 Immunex Corporation Cytokine designated LERK-6
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US6057124A (en) 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
ATE390933T1 (en) 1995-04-27 2008-04-15 Amgen Fremont Inc HUMAN ANTIBODIES AGAINST IL-8 DERIVED FROM IMMUNIZED XENOMICES
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
DE19534177A1 (en) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclic adhesion inhibitors
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5827673A (en) * 1996-08-13 1998-10-27 Akira Matsumori Method of detecting myocardial infarction
WO1998019696A1 (en) 1996-11-05 1998-05-14 Smithkline Beecham Corporation Hepatocyte growth factor antagonists
DK1500329T3 (en) 1996-12-03 2012-07-09 Amgen Fremont Inc Human antibodies that specifically bind TNF-alpha
CO4950519A1 (en) 1997-02-13 2000-09-01 Novartis Ag PHTHALAZINES, PHARMACEUTICAL PREPARATIONS THAT UNDERSTAND THEM AND THE PROCESS FOR THEIR PREPARATION
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
CA2205096C (en) * 1997-05-09 2001-10-09 Ibm Canada Limited-Ibm Canada Limitee A system for remote debugging of client/server applications
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6232456B1 (en) * 1997-10-06 2001-05-15 Abbott Laboratories Serine protease reagents and methods useful for detecting and treating diseases of the prostate
RS49779B (en) 1998-01-12 2008-06-05 Glaxo Group Limited, BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS
ATE430149T1 (en) 1998-03-04 2009-05-15 Bristol Myers Squibb Co HETEROCYCLE SUBSTITUTED IMIDAZOPYRAZINE AS PROTEIN TYROSINE KINASE INHIBITORS
CN1255927A (en) 1998-03-12 2000-06-07 上海第二医科大学 Human neuroglia mature factor (GMF) beta homologous gene (CBFBOE11)
JP2002507584A (en) 1998-03-26 2002-03-12 ロング アイランド ジューイッシュ メディカル センター Use of scattering factors to enhance angiogenesis
CN1305896C (en) * 1998-05-06 2007-03-21 基因技术股份有限公司 Protein purification by ion exchange chromatography
EA005032B1 (en) 1998-05-29 2004-10-28 Сьюджен, Инк. Pyrrole substituted 2-indolinone (variants), pharmaceutical composition (variants), method for modulation of catalytic activity method for treating and preventing a protein kinase related disorders in an organism
UA60365C2 (en) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Isothiazole derivatives, a method for preparing thereof, a pharmaceutical composition and a method for treatment of hyperproliferative disease of mammal
CA2336848A1 (en) 1998-07-10 2000-01-20 Merck & Co., Inc. Novel angiogenesis inhibitors
WO2000012560A1 (en) * 1998-08-28 2000-03-09 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
EP1109555A4 (en) 1998-08-31 2001-11-21 Merck & Co Inc NEW ANGIOGENIC INHIBITORS
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
HK1042251B (en) 1999-01-13 2012-07-20 Bayer Healthcare Llc Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
AU766081B2 (en) 1999-03-30 2003-10-09 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
AU783960B2 (en) 1999-06-07 2006-01-05 Immunex Corporation Tek antagonists
PL203782B1 (en) 1999-11-05 2009-11-30 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
WO2001034650A1 (en) * 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Hgf-sf monoclonal antibody combinations
JP5336686B2 (en) 1999-11-24 2013-11-06 スージェン， インク． Formulations for drugs that can be ionized as free acids or free bases
US6515004B1 (en) 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
PT1255829E (en) 2000-02-11 2009-11-26 Genentech Inc Inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization
ATE358718T1 (en) 2000-02-25 2007-04-15 Immunex Corp INTEGRIN ANTAGONISTS
WO2001068707A1 (en) 2000-03-13 2001-09-20 Eli Lilly And Company Human hepatocyte growth factor activator inhibitor homologue
GB0006398D0 (en) * 2000-03-16 2000-05-03 Novartis Ag Organic compounds
US6749847B2 (en) * 2000-03-30 2004-06-15 The University Of Connecticut Hybrid cytokine of IL-7 and β-chain of hepatocyte growth factor
JP2003533187A (en) 2000-05-03 2003-11-11 アムジエン・インコーポレーテツド Modified peptide containing Fc domain as therapeutic agent
JP3597140B2 (en) * 2000-05-18 2004-12-02 日本たばこ産業株式会社 Human monoclonal antibody against costimulatory molecule AILIM and pharmaceutical use thereof
AU7785401A (en) 2000-06-29 2002-01-14 Long Island Jewish Res Inst Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US6630500B2 (en) 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
ES2556946T3 (en) 2000-12-21 2016-01-21 Novartis Ag Pyrimidinamines as angiogenesis modulators
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
CA2472383A1 (en) 2001-12-27 2003-07-17 Van Andel Research Institute Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
CN1376923A (en) * 2002-04-08 2002-10-30 刘友华 Method for detecting liver cell growth factor
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
US7220410B2 (en) * 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
EP1636593B9 (en) * 2003-06-06 2009-12-16 Genentech, Inc. Modulating the interaction between hgf beta chain and c-met
CN103755807A (en) 2003-07-18 2014-04-30 安姆根有限公司 Specific binding agents to hepatocyte growth factor
AR059922A1 (en) 2006-04-01 2008-05-07 Galaxy Biotech Llc HUMANIZED MONOCLONAL ANTIBODIES FOR THE GROWTH FACTOR OF HEPATOCITS
JP4686634B2 (en) 2006-06-02 2011-05-25 アベオ ファーマシューティカルズ， インコーポレイテッド Hepatocyte growth factor (HGF) binding protein
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
HK1087437A1 (en) 2006-10-13
JP2011079837A (en) 2011-04-21
NO20060600L (en) 2006-04-18
ES2523837T3 (en) 2014-12-01
IL172906A0 (en) 2006-06-11
JP2012235783A (en) 2012-12-06
CN103755807A (en) 2014-04-30
CN101124240B (en) 2013-12-18
DK1648998T3 (en) 2015-01-05
PT1648998E (en) 2014-11-04
ZA200803050B (en) 2010-08-25
MXPA06000508A (en) 2006-04-05
EP2341067A1 (en) 2011-07-06
AR086510A2 (en) 2013-12-18
CN103880955A (en) 2014-06-25
EA015363B1 (en) 2011-06-30
CN101124240A (en) 2008-02-13
CA2532027A1 (en) 2005-02-24
EP1648998B1 (en) 2014-10-01
US8609090B2 (en) 2013-12-17
AU2004265595A1 (en) 2005-02-24
RS20050975A (en) 2008-06-05
PL1648998T3 (en) 2015-03-31
WO2005017107A3 (en) 2007-03-01
ZA200601353B (en) 2008-11-26
MEP31408A (en) 2010-10-10
US20050118643A1 (en) 2005-06-02
KR20060054321A (en) 2006-05-22
TW200524958A (en) 2005-08-01
US20140154243A1 (en) 2014-06-05
RS53476B (en) 2014-12-31
TWI395756B (en) 2013-05-11
AR042955A1 (en) 2005-07-13
JP2007530003A (en) 2007-11-01
KR101254371B1 (en) 2013-05-02
TWI476206B (en) 2015-03-11
TW201319088A (en) 2013-05-16
EA200600233A1 (en) 2007-04-27
AU2004265595B2 (en) 2011-12-08
WO2005017107A2 (en) 2005-02-24
JP2012051901A (en) 2012-03-15
TW201319087A (en) 2013-05-16
SI1648998T1 (en) 2015-01-30
CA2532027C (en) 2016-06-14
JP5750021B2 (en) 2015-07-15
KR20110129988A (en) 2011-12-02
BRPI0412885A (en) 2006-10-03
HK1199266A1 (en) 2015-06-26
SG131943A1 (en) 2007-05-28
NZ544797A (en) 2011-04-29
EP1648998A2 (en) 2006-04-26
JP5105874B2 (en) 2012-12-26
JP5543315B2 (en) 2014-07-09
EP1648998A4 (en) 2007-11-14

Similar Documents

Publication Publication Date Title
AR086511A2 (en) UNION AGENTS SPECIFIC TO THE GROWTH FACTOR OF HEPATOCITS
AR111209A2 (en) HER2 ANTIBODY COMPOSITION
ES2542853T3 (en) Method to treat myasthenia gravis
PE20021080A1 (en) A SPECIFIC ANTIBODY FAPO BIBH1 IN THE TREATMENT OF CANCER
AR086272A2 (en) ANTI-FACTOR D HUMANIZED ANTIBODIES AND THEIR USES
AR033978A1 (en) ANTIBODY MOLECULA WITH SPECIFICITY FOR HUMAN ALPHA TUMOR NECROSIS FACTOR AND USES OF THE SAME
PT1548032E (en) KDR PEPTIDES AND VACCINES THAT CONTAIN THEM
AR045247A1 (en) ANTI-IGF-1R MODIFIED HUMAN ANTIBODIES
ECSP105739A (en) NEUTRALIZATION ANTIBODIES AGAINST GDF-8
ES2539790T3 (en) Methods and compositions to modulate hyperstabilized c-met
ES2689746T3 (en) Monoclonal antibodies against claudin-18 for cancer treatment
DE60224291D1 (en) SYSTEM FOR ANTIBODY EXPRESSION AND SYNTHESIS
AR075790A2 (en) ANTI-NGF ANTIBODIES NEUTRALIZING HUMANS AS SELECTIVE INHIBITORS OF THE NGF VIA (NEURAL GROWTH FACTOR)
EA200800268A1 (en) COMBINED THERAPY WITH ANTIBODY AGAINST CTLA-4 AND CONTAINING A CpG-MOTIVE SYNTHETIC OLYGESOXYNECLETOSIDE FOR THE TREATMENT OF MALIGNANT TUMOR
AR080564A1 (en) METHODS FOR THE TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH THE RECEIVER OF THE HUMAN EPIDERMIC GROWTH FACTOR-3 (HER-3)
AR103868A1 (en) ANTI-CD47 ANTIBODIES AS THERAPEUTIC AGENTS
AR073425A1 (en) ANTITUMORAL COMBINATIONS CONTAINING ANTIBODIES THAT SPECIFICALLY RECOGNIZE CD38 AND CITARABINE
CO6220978A2 (en) ANTIBODIES DIRECTED TO PROTEIN-1 CHEMIO-TACTICS OF MONOCITS (MCP-1) AND ITS USES
CL2008003527A1 (en) Antibody conjugate or antigen-binding portion thereof, which binds to protein tyrosine kinase 7 (ptk-7 / cck4); composition comprising it; antibody acidifying nullceic acid; vector and host cell; use of the conjugate to treat or prevent a disease of tumor cells expressing ptk7
ECSP045146A (en) SMALL MOLECULES FOR THE TREATMENT OF ABNORMAL CELL GROWTH
AR031250A1 (en) COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF CANCER DE PULMON
PE20081004A1 (en) INDUCING AGENTS OF CELLULAR DEATH
DK1675954T3 (en) Nucleic acids useful in triggering tumor cell mortality
PE20021098A1 (en) CD44v6 SPECIFIC ANTIBODIES
DK1871391T3 (en) EVEN RETROVIRUS AND PROTEINS CODED BY ENV TARGETED FOR CANCER TREATMENT

Legal Events

Date Code Title Description
FB Suspension of granting procedure